PUBLISHER: GlobalData | PRODUCT CODE: 1663588
PUBLISHER: GlobalData | PRODUCT CODE: 1663588
BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Breast cancer type 1 (BRCA1) and Breast cancer type 1 (BRCA1 gene tests, under the overall umbrella of BRCA Tests, are carried out to detect gene rearrangements within blood samples; the outcome of which may guide therapies and prophylactic actions to treat or prevent certain types of breast and ovarian cancer.
Breast cancer is generally subdivided into different categories, depending on expression levels of cellular receptors for estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2). Since aberrant activity contributes to tumour genesis, molecular-targeted therapies exist for breast cancer patients that express one or more of these three receptors.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed BRCA tests and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: NGeneBio Co Ltd, Agilent Technologies Inc, Illumina Inc, NimaGen BV, Qiagen NV, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, MRC-Holland BV, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to: